Home > Resources > Whitepapers > Uniform and Scalable EB Formation for Drug Discovery and Regenerative Medicine Applications

Uniform and Scalable EB Formation for Drug Discovery and Regenerative Medicine Applications

July 20, 2012

The developmental versatility of pluripotent stem cells (PSCs) offers a powerful approach for directing cell fate, and these cells are a promising source of progenitors and terminally differentiated somatic cells for cell replacement therapy and drug screening applications. In culture, PSCs have a unique trait of unlimited propagation while retaining their inherent potential to differentiate into cells from the three embryonic germ layers. When plated onto a non-adherent culture dish, these cells aggregate to form embryoid bodies (EBs) which undergo a process of spontaneous differentiation that closely imitates early human embryogenesis.

Spotlight

BIOTECHNOLOGY RESEARCH FOUNDATION

Biotechnology research foundation is available to undertake consultancy projects or contribute in an advisory role in the following areas , Bio remediation, Environmental Impact Assessment , Designing Monitoring and Verification mechanisms for Carbon Emissions , Soil Testing, Hydroponics, Tissue Culture , DNA , GMO Monitoring, Building Waste Treatment Technologies and Agricultural Biotechnology

OTHER WHITEPAPERS

DIGITAL BIOTECH IS MISSION-CRITICAL TO MODERNA

whitePaper | May 20, 2022

We are living in a unique time in which the world is changing faster than ever. This largely is due to an influx and infusion of digital technologies that are reinventing and reimagining businesses across nearly every sector, and dramatically shifting societal and economic interactions. While the life science industry has, to some extent, adopted various digital technologies, it has not had a significant digital transformation in how it does business.

Accurate and reliable cell counting using holographic microscopy and machine learning algorithms

whitePaper | August 11, 2022

Reliable and accurate cell counts are crucial for many different purposes such as the maintenance of cell cultures in biological research or in-process controls in industrial bioprocessing.

Effective solutions for global challenges

whitePaper | April 24, 2023

Despite challenging global conditions, the Swiss biotech industry was able to raise more than CHF 1.33 billion in 2022, with roughly CHF 0.78 billion collected by public companies and the remaining CHF 0.55 billion collected by private companies.

A digital ecosystem for Clinical Trails

whitePaper | July 30, 2021

Clinical trials are complex, lengthy, and resource-inefficient. The clinical research industry is responsible for the delivery of medical solutions to society by systematically evaluating their safety and efficacy in humans during so-called clinical trials. As exemplified by the COVID-19 pandemic, a steady and efficient influx of vaccines, therapeutics, and other innovative medical solutions is critical for meeting society’s current and future medical needs. Unfortunately, the industry faces several persistent issues that make clinical trial operations overly complex, lengthy, and resource-inefficient.

Leveraging innovations in plasmid manufacturing to bring advanced therapies to market

whitePaper | December 13, 2022

The global demand for plasmid DNA has increased dramatically in recent years, fueled by a surge in the clinical development of next-generation cell and gene therapy products and more recently by the success of COVID-19 vaccines.

Next Generation Therapies and related Life Sciences topics

whitePaper | January 16, 2022

All gene therapies insert engineered DNA/RNA into living cells to make or modify new proteins